Pharmacologic treatment of schizophrenia

Biological Psychiatry

Volumn 46, Issue 10, 1999, Pages 1396-1408

  Kane, John M ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Psychopharmacology antipsychotic medication; Schizophrenia; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

AGRANULOCYTOSIS; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; EYE TOXICITY; HUMAN; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; SCHIZOPHRENIA; SUICIDAL BEHAVIOR;

EID: 0032704664     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00059-1     Document Type: Review

References (96)

1. Albanese M.J., Khantzian E.J., Mercy F.L., Green A.I. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry. 151:1994;780-781.
2. Arranz M., Collier D., Sodhi M., et al. Association between clozapine response and allelic variation in 5-HT 2A receptor gene. Lancet. 345:1995;281-282.
3. Arvanitis L.A., Miller D.G. Multiple fixed doses of "SEROQOUEL" (quetiapine) in patients with acute exacerbation of schizophrenia a comparison with haloperidol and placebo . Biol Psychiatry. 42:1997;233-246.
4. Baldacchino A.M., Stubbs J.H., Nevison-Andrews D. The use of olanzapine in non-compliant or treatment-resistant clozapine populations in hospital. Pharm J. 260:1998;207-209.
5. Beasley C.M., Tollefson G., Tran P., et al. Olanzapine versus placebo and haloperidol acute phase results of the North American double-blind olanzapine trial . Neuropsychopharmacology. 14:1996;111-123.
6. Bjorndal N., Bjerre M., Gerlach J., et al. High dosage haloperidol therapy in chronic schizophrenic patients a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin . Psychopharmacology. 67:1980;17-23.
7. Bondolfi G., Dufour H., Patris M., et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia a randomized double-blind study . Am J Psychiatry. 155:1998;499-504.
8. Borison R.L., Pathiraja A.P., Diamond B.I., Meibach R.C. Risperidone; clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 28:1992;213-218.
9. Breier A., Buchanan R.W., Kirkpatrick B., et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 151:1994;20-26.
10. Breier A., Hamilton S.H. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry. 45:1999;403-411.
11. Buckley P., Thompson P., Way L., Melter H.Y. Substance abuse among patients with treatment-resistant schizophrenia characteristics and implications for clozapine in therapy . Am J Psychiatry. 151:1994;385-389.
12. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone or haloperidol. Schizophr Res. 29:1998;152-153.
13. Carpenter W.T. Jr, Conley R.R., Buchanan R.W., Breier A., Tamminga C.A. Patient response and resource management another view of clozapine treatment of schizophrenia . Am J Psychiatry. 152:1995;827-832.
14. Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al (1990): Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 147:1138-1148 [Erratum, Am J Psychiatry 1991;148:819].
15. Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al (1990): Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 147:1138-1148 [Erratum, Am J Psychiatry 1991;148:819].
16. Casey D.E. Clozapine neuroleptic-induced EPS and tardive dyskinesia . Psychopharmacology. 99:(suppl):1989;S47-S53.
17. Ceskova E., Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenia and schizoaffective psychoses. Pharmacopsychiatry. 26:1993;121-124.
18. Chouinard G, Jones B, Remington G, et al (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40 [Erratum, J Clin Psychopharmacol 1993;13:149].
19. Chouinard G, Jones B, Remington G, et al (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40 [Erratum, J Clin Psychopharmacol 1993;13:149].
20. Christison G.W., Kirch D.G., Wyatt R.J. When symptoms persist choosing among alternative somatic treatments for schizophrenia. Schizophr Bull. 17:1991;217-245.
21. Claus A., Bollen J., De Cuyper H., et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients a multicentre double-blind comparative study . Acta Psychiatr Scand. 85:1992;295-305.
22. Conley R.R., Taminga C.A., Bartko J.J., et al. Olanzapine compared with clopromazine in treatment-resistant schizophrenia. Am J Psychiatry. 155:1998;914-920.
23. Davis J.M. Overview maintenance therapy in psychiatry. I. Schizophrenia . Am J Psychiatry. 132:1975;1237-1245.
24. Davis JM, Matalon L, Watanabe MD, Blake L (1994): Depot antipsychotic drugs: place in therapy. Drugs 47:741-773 [Erratum, Drugs 1994;48:616].
25. Davis JM, Matalon L, Watanabe MD, Blake L (1994): Depot antipsychotic drugs: place in therapy. Drugs 47:741-773 [Erratum, Drugs 1994;48:616].
26. Erlenmeyer-Kimling L., Cornblatt B.A., Rock D., et al. The New York High-Risk Project Anhedonia, attentional deviants, and psychopathology . Schizophr Bull. 19:1993;141-153.
27. Essock S.M., Hargreaves W.A., Covell N.H., Goethe J. Clozapine's effectiveness for patients in state hospitals results from a randomized trial . Psychopharmacol Bull. 32:1996;683-697.
28. Essock S.M., Hargreaves W.A., Dohm F.-A., Goethe J., Carver L., Hipshman L. Clozapine eligibility among state hospital patients. Schizophr Bull. 22:1996;15-25.
29. Flynn S.W., MacEwan G.W., Altman S., Kopala L.C. An open comparison of clozapine and risperidone. Pharmacopsychiatry. 31:1998;25-29.
30. Gilbert P.L., Harris N.J., McAdams L.A., Jeste D.V. Neuroleptic withdrawal in schizophrenic patients a review of the literature . Arch Gen Psychiatry. 52:1995;173-188.
31. Glazer W.M., Kane J.M. Depot neuroleptic therapy an underutilized treatment option . J Clin Psychiatry. 53:1992;426-433.
32. Gold J.M., Harvey P.D. Cognitive deficits in schizophrenia. Psychiatr Clin North Am. 16:1993;295-312.
33. Goldman R.S., Bates J.A., Bilder R.M., Kane J., Schooler N., Marter S. The effects of clozapine and haloperidol on memory functioning in treatment-refractory schizophrenics. Schizophr Res. 18:1996;221.
34. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 153:1996;321-330.
35. Green M.F., Marshal V.D., Wirshing W.C., et al. Risperidone effects on verbal working memory. Schizophr Res. 24:1997;214.
36. Hagger C., Buckley P., Kenny J.T., Freedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 34:1993;702-712.
37. Hegarty J.D., Baldessarini R.J., Tohen M., Waternaux C., Open G. One hundred years of schizophrenia a meta-analysis of the outcome literature . Am J Psychiatry. 151:1994;1409-1416.
38. Herz M.I., Glazer W.M., Mostert M.A., et al. Intermittent vs maintenance medication in schizophrenia two-year results . Arch Gen Psychiatry. 48:1991;333-339.
39. Herz M.I., Liberman R.P., Lieberman Ja, et al. American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 154:(suppl):1997;1-63.
40. Hogarty G.E., McEvoy J.P., Munetz M., et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia results in a two-year controlled study. Arch Gen Psychiatry. 45:1988;797-805.
41. Hogarty G.E., Schooler N., Ulorich R.F., Mussare F., Ferro P., Horron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients relapse analysis of two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride . Arch Gen Psychiatry. 36:1979;1283-1294.
42. Janicak P.G., Davis J.M., Preskorn S.H., Ayd F.J. Jr. Principles and Practice of Psychopharmacotherapy. 1993;104-106 Williams & Wilkins, Baltimore.
43. Johnson D.A., Ludlow J.M., Street K., Taylor R.D. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilized out-patients with schizophrenia. Br J Psychiatry. 151:1987;634-638.
44. Jolley A.G., Hirsch S.R., McRink A., Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients clinical outcome at one year . Br Med J. 298:1989;985-990.
45. Jolley A.G., Hirsch S.R., Morrison E., McRink A., Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients clinical and social outcome at two years . BMJ. 301:1990;837-842.
46. Kane J.M. Compliance issues in outpatient treatment. J Clin Psychopharmacol. 5:1985;22S-27S.
47. Kane J.M. Tardive dyskinesia epidemiological and clinical presentation . Bloom F.E., Kupfer D.J. Psychopharmacology The Fourth Generation of Progress . 1995;1485-1495 Raven Press, New York.
48. Kane J.M. Who shall decide when doctors disagree? Am J Psychiatry. 153:1996;1507-1508.
49. Kane J.M. Schizophrenia. N Engl J Med. 334:1996;34-41.
50. Kane J.M., Borenstein M. Compliance in the long-term treatment of schizophrenia. Psychopharmacol Bull. 21:1985;23-27.
51. Kane J.M., Davis J.M., Schooler N.R., Marder S.R., Brauzer B., Casey D.E. A one-year comparison of four dosages of haloperidol decanoate [abstract]. Schizophr Res. 9:1993;239-240.
52. Kane J.M., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic a double blind comparison with clopromazine . Arch Gen Psychiatry. 45:1988;789-796.
53. Kane J.M., Lieberman J.A. Maintenance pharmacotherapy in schizophrenia. Meltzer H.Y. Psychopharmacology The Third Generation of Progress . 1987;1103-1109 Raven Press, New York.
54. Kane J.M., Rifkin A., Quitkin F., Klein D.F. Antipsychotic drug blood levels and clinical outcome. Klein D.F., Gittelman-Klein R. Progress in Psychiatric Drug Treatment. 1976;399-408 Brunner Mazel, New York.
55. Kane J.M., Rifkin A., Woerner M.G., et al. Low-dose neuroleptic treatment of outpatient schizophrenia. I. Preliminary results for relapse rates. Arch Gen Psychiatry. 40:1983;893-896.
56. Kane J.M., Smith J. Tardive dyskinesia prevalence and risk factors 1959-1979 . Arch Gen Psychiatry. 39:1982;473-481.
57. Kane J.M., Woerner M.G., Pollack S., Safferman A.Z., Lieberman J.A. Does clozapine cause tardive dyskinesia? J Clin Psychiatry. 54:1993;327-330.
58. Kane J.M., Woerner M.G., Sarantakos S. Depot neuroleptics a comparative review of standard, intermediate, and low-dose regimens . J Clin Psychiatry. 47:(suppl):1986;30-33.
59. Kinon B.J., Kane J.M., Johns C., Perovich R., Ismi M., Koreen A. Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacol Bull. 29:1993;309-314.
60. Kissling W. Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. 1991;Springer-Verlag, Berlin, Germany.
61. Klein D.F., Davis J.M. Diagnosis and Drug Treatment of Psychiatric Disorders. 1969;Williams & Wilkins, Baltimore.
62. Klieser E., Lehman E., Kinzler E., et al. Randomized, double-blind controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol. 15:1995;45S-51S.
63. Levinson D.F., Simpson G.M., Singh H., et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry. 47:1990;761-768.
64. Malhotra A.K., Goldman D., Ozaki N., Breier A., Buchanan R., Pickar D. Lack of association between poly-morphisms in the 5-HT 2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry. 153:1996;1092-1094.
65. Mallya A.R., Roos P.D., Roebuck-Colgan K. Restraint, seclusion and clozapine. J Clin Psychiatry. 53:1992;395-397.
66. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 151:1994;825-835.
67. Marder S.R., Van Putten T., Mintz J., et al. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry. 41:1984;1025-1029.
68. Marder S.R., Van Putten T., Mintz J., Lebell M., McKenzie J., May P.R. Low-and conventional-dose maintenance therapy with fluphenazine decanoate two-year outcome . Arch Gen Psychiatry. 44:1987;518-521.
69. Martin J., Gomez J.-C., Garcia-Bernardo E., Cuesta M., Alvarez E., Gurpegui M. Olanzapine and treatment-refractory schizophrenia results of an open-label study . J Clin Psychiatry. 58:1997;479-493.
70. Meltzer H.Y. Clozapine is another view valid? Am J Psychiatry. 152:1995;821-825.
71. Meltzer H.Y., Okayli O. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia impact on risk-benefit assessment . Am J Psychiatry. 152:1995;183-190.
72. Muller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients an international double-blind parallel-group study versus haloperidol . Clin Neuropharmacol. 15:(suppl 1):1992;90A-91A.
73. Peuskens J., Link C.G.G. A comparison of quetiapine and clopromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 96:1997;265-273.
74. Pickar D., Owen R.R., Litman R.E., Konicki E., Gutierrez R., Rappoport M.H. Clinical and biologic response to clozapine in patients with schizophrenia crossover comparison with fluphenazine . Arch Gen Psychiatry. 49:1992;345-353.
75. Pietzcker A., Gaebel W., Kopcke W., et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of German multicenter study. J Psychiatr Res. 27:1993;321-339.
76. Pollack S., Woerner M.G., Howard A., Fireworker R.B., Kane J.M. Clozapine reduces rehospitalization among schizophrenia patients. Psychopharmacol Bull. 34:1998;89-92.
77. Prien R.F., Cole J.O. High dose of chlorpromazine in chronic schizophrenia. Arch Gen Psychiatry. 18:1968;482-495.
78. Quitkin F., Rifkin A., Klein D. Very high dosage vs. standard dosage fluphenazine in schizophrenia. A double-blind study of non-chronic treatment-refractory patients. Arch Gen Psychiatry. 32:1975;1276-1281.
79. Regier D.A., Farmer M.E., Rae D.S., et al. Co-morbidity of mental disorders with alcohol and other drug abuse. JAMA. 264:1990;2511-2518.
80. Remington G., Pollock B., Voineskos G., Reed K., Coulter K. Acutely psychotic patients receiving high-dose haloperidol therapy. J Clin Psychopharmacol. 13:1993;41-45.
81. Rifkin A., Doddi S., Karajgi B., Borenstein M., Wachspress M. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry. 48:1991;166-170.
82. Rosenheck R., Cramer J., Xu W., et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med. 337:1997;809-815.
83. Schooler N (1998, May): Comparing new anti-psychotic medications: what do the data say. Presented at the Society of Biological Psychiatry Annual Meeting, Toronto Canada.
84. Schooler N.R., Keith S.J., Severe J.B., et al. Relapse and reshospitalization during maintenance treatment of schizophrenia. Arch Gen Psychiatry. 54:1997;453-463.
85. Shalev A., Hermash H., Rothberg J., Munitz H. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatr Scand. 87:1993;86-91.
86. Shaner A., Khalsa M.A., Roberts L., Wilkins J., Anglin D., Hsieh S.C. Unrecognized cocaine use among schizophrenic patients. Am J Psychiatry. 150:1993;758-762.
87. Tollefson G.D., Beasley C.M. Jr, Tamura R.N., Tran P.V., Potvin J.H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 154:1997;1248-1254.
88. Tollefson G.D., Beasley C.M., Tran P., Street J.S., Kruger J.A., Tamura R.N. Olanzapine versus haloperidol and the treatment of schizophrenia and schizoaffective and schizophreniform disorders results of an international collaborative trial . Am J Psychiatry. 154:1997;457-465.
89. Tollefson G.D., Sanger T.M., Lou Y., Thieme M.E. Depressive signs and symptoms in schizophrenia a trial of olanzapine and haloperidol . Arch Gen Pyschiatry. 55:1998;250-258.
90. Tran P.V., Hamilton S.H., Kuntz A.J., et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 17:1997;407-418.
91. Van Putten T., Marder S.R., Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry. 47:1990;754-758.
92. Viguera A.C., Baldessarini R.J., Hegarty J.D., et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 54:1997;49-55.
93. Volavka J., Cooper T., Czobor P., et al. Haloperidol blood levels and clinical effects. Arch Gen Psychiatry. 49:1992;354-361.
94. Wahlbeck K (1998, February 7-13): Evidence of clozapine effectiveness in schizophrenia. Presented at the Ninth Biennial Winter Workshop on Schizophrenia, Davos Switzerland.
95. Weiden P.J., Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 21:1995;419-429.
96. Zimbroff D.L., Kane J.M., Tamminga C.A., et al. A controlled, dose-response study of sertindole and haloperidol in schizophrenia. Am J Psychiatry. 154:1997;782-791.